Future Clinical Development

GBP will be responsible for all clinical development and commercialization costs of ADXS-HPV vaccine in the GBP territory:
. GBP will partner with Advaxis to conduct registration trials of ADXS-HPV for the treatment of advanced cervical cancer. 
. GBP will conduct exclusively a Phase 2 trial of ADXS-HPV for the treatment of HPV(+) lung cancer. 

GBP will explore the use of ADXS-HPV with Advaxis in several other indications including head and neck and anal cancers.